Here, we presented compelling evidence to support a therapeutic potential of pro-DCD and PEGylation derivatives in pre-clinical model of sepsis by attenuating dysregulated inflammation and possibly facilitating LC3-associated phagocytosis and/or autophagic degradation of engulfed pathogens. Here, MAP1LC3A is linked to Sepsis.